Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the prebiologic therapy era

Stefan D. Holubar, Eric Dozois, Edward Vincent Loftus, Jr, Swee H. Teh, Luis A. Benavente, W. Scott Harmsen, Bruce G. Wolff, Robert R. Cima, David Larson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Primary intestinal lymphoma in the setting of inflammatory bowel disease (IBD) is uncommon and may be associated with immune suppressive therapy. We report clinical features and outcomes in patients with both conditions prior to use of biologic therapy. Methods: All patients with primary intestinal lymphoma and IBD at our institution from 1960-2000 were retrospectively identified. Data reported are frequency (proportion) or median (interquartile range). Kaplan-Meier analysis was performed. Results: Fifteen patients were identified: 14 (93%) were male, 10 (66%) had Crohn's disease. Median age at diagnosis of IBD and lymphoma was 30 (22-51) and 47 (28-68) years, respectively, with bloody diarrhea the most common presenting symptom for each diagnosis. Lymphoma location was colorectal in nine (60%), small bowel in four (27%), and one (6.25%) each: stomach, duodenum, and ileal pouch. Treatments were surgery plus chemotherapy (n = 6), surgery alone (n = 3), chemotherapy alone (n = 2), chemotherapy and radiation (n = 1), surgery and radiation (n = 1); two patients died before treatment. Most patients (n = 11, 73%) were Ann Arbor stages I or II. Large cell B-type histology was most common (n = 9, 60%). Three patients died within 30 days of lymphoma diagnosis. Survival free of death from lymphoma at 1- and 5-years was 78% and 63%, respectively, and was associated with advanced lymphoma stage (P = 0.004). Conclusions: Diagnosis and treatment of primary intestinal lymphoma in patients with IBD can be challenging and requires a high index of suspicion. Optimal survival requires multimodality therapy.(Inflamm Bowel Dis 2010;)

Original languageEnglish (US)
Pages (from-to)1557-1563
Number of pages7
JournalInflammatory Bowel Diseases
Volume17
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Inflammatory Bowel Diseases
Lymphoma
Therapeutics
Drug Therapy
Radiation
Colonic Pouches
Biological Therapy
Survival
Kaplan-Meier Estimate
Duodenum
Crohn Disease
Diarrhea
Stomach
Histology

Keywords

  • biologic therapy
  • Crohn's disease
  • gastrointestinal carcinogenesis
  • inflammatory bowel disease
  • infliximab
  • surgery lymphoma
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Primary intestinal lymphoma in patients with inflammatory bowel disease : A descriptive series from the prebiologic therapy era. / Holubar, Stefan D.; Dozois, Eric; Loftus, Jr, Edward Vincent; Teh, Swee H.; Benavente, Luis A.; Harmsen, W. Scott; Wolff, Bruce G.; Cima, Robert R.; Larson, David.

In: Inflammatory Bowel Diseases, Vol. 17, No. 7, 07.2011, p. 1557-1563.

Research output: Contribution to journalArticle

Holubar, Stefan D. ; Dozois, Eric ; Loftus, Jr, Edward Vincent ; Teh, Swee H. ; Benavente, Luis A. ; Harmsen, W. Scott ; Wolff, Bruce G. ; Cima, Robert R. ; Larson, David. / Primary intestinal lymphoma in patients with inflammatory bowel disease : A descriptive series from the prebiologic therapy era. In: Inflammatory Bowel Diseases. 2011 ; Vol. 17, No. 7. pp. 1557-1563.
@article{e35285ec75bb41479a2a5b6f9ab2119a,
title = "Primary intestinal lymphoma in patients with inflammatory bowel disease: A descriptive series from the prebiologic therapy era",
abstract = "Background: Primary intestinal lymphoma in the setting of inflammatory bowel disease (IBD) is uncommon and may be associated with immune suppressive therapy. We report clinical features and outcomes in patients with both conditions prior to use of biologic therapy. Methods: All patients with primary intestinal lymphoma and IBD at our institution from 1960-2000 were retrospectively identified. Data reported are frequency (proportion) or median (interquartile range). Kaplan-Meier analysis was performed. Results: Fifteen patients were identified: 14 (93{\%}) were male, 10 (66{\%}) had Crohn's disease. Median age at diagnosis of IBD and lymphoma was 30 (22-51) and 47 (28-68) years, respectively, with bloody diarrhea the most common presenting symptom for each diagnosis. Lymphoma location was colorectal in nine (60{\%}), small bowel in four (27{\%}), and one (6.25{\%}) each: stomach, duodenum, and ileal pouch. Treatments were surgery plus chemotherapy (n = 6), surgery alone (n = 3), chemotherapy alone (n = 2), chemotherapy and radiation (n = 1), surgery and radiation (n = 1); two patients died before treatment. Most patients (n = 11, 73{\%}) were Ann Arbor stages I or II. Large cell B-type histology was most common (n = 9, 60{\%}). Three patients died within 30 days of lymphoma diagnosis. Survival free of death from lymphoma at 1- and 5-years was 78{\%} and 63{\%}, respectively, and was associated with advanced lymphoma stage (P = 0.004). Conclusions: Diagnosis and treatment of primary intestinal lymphoma in patients with IBD can be challenging and requires a high index of suspicion. Optimal survival requires multimodality therapy.(Inflamm Bowel Dis 2010;)",
keywords = "biologic therapy, Crohn's disease, gastrointestinal carcinogenesis, inflammatory bowel disease, infliximab, surgery lymphoma, ulcerative colitis",
author = "Holubar, {Stefan D.} and Eric Dozois and {Loftus, Jr}, {Edward Vincent} and Teh, {Swee H.} and Benavente, {Luis A.} and Harmsen, {W. Scott} and Wolff, {Bruce G.} and Cima, {Robert R.} and David Larson",
year = "2011",
month = "7",
doi = "10.1002/ibd.21516",
language = "English (US)",
volume = "17",
pages = "1557--1563",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Primary intestinal lymphoma in patients with inflammatory bowel disease

T2 - A descriptive series from the prebiologic therapy era

AU - Holubar, Stefan D.

AU - Dozois, Eric

AU - Loftus, Jr, Edward Vincent

AU - Teh, Swee H.

AU - Benavente, Luis A.

AU - Harmsen, W. Scott

AU - Wolff, Bruce G.

AU - Cima, Robert R.

AU - Larson, David

PY - 2011/7

Y1 - 2011/7

N2 - Background: Primary intestinal lymphoma in the setting of inflammatory bowel disease (IBD) is uncommon and may be associated with immune suppressive therapy. We report clinical features and outcomes in patients with both conditions prior to use of biologic therapy. Methods: All patients with primary intestinal lymphoma and IBD at our institution from 1960-2000 were retrospectively identified. Data reported are frequency (proportion) or median (interquartile range). Kaplan-Meier analysis was performed. Results: Fifteen patients were identified: 14 (93%) were male, 10 (66%) had Crohn's disease. Median age at diagnosis of IBD and lymphoma was 30 (22-51) and 47 (28-68) years, respectively, with bloody diarrhea the most common presenting symptom for each diagnosis. Lymphoma location was colorectal in nine (60%), small bowel in four (27%), and one (6.25%) each: stomach, duodenum, and ileal pouch. Treatments were surgery plus chemotherapy (n = 6), surgery alone (n = 3), chemotherapy alone (n = 2), chemotherapy and radiation (n = 1), surgery and radiation (n = 1); two patients died before treatment. Most patients (n = 11, 73%) were Ann Arbor stages I or II. Large cell B-type histology was most common (n = 9, 60%). Three patients died within 30 days of lymphoma diagnosis. Survival free of death from lymphoma at 1- and 5-years was 78% and 63%, respectively, and was associated with advanced lymphoma stage (P = 0.004). Conclusions: Diagnosis and treatment of primary intestinal lymphoma in patients with IBD can be challenging and requires a high index of suspicion. Optimal survival requires multimodality therapy.(Inflamm Bowel Dis 2010;)

AB - Background: Primary intestinal lymphoma in the setting of inflammatory bowel disease (IBD) is uncommon and may be associated with immune suppressive therapy. We report clinical features and outcomes in patients with both conditions prior to use of biologic therapy. Methods: All patients with primary intestinal lymphoma and IBD at our institution from 1960-2000 were retrospectively identified. Data reported are frequency (proportion) or median (interquartile range). Kaplan-Meier analysis was performed. Results: Fifteen patients were identified: 14 (93%) were male, 10 (66%) had Crohn's disease. Median age at diagnosis of IBD and lymphoma was 30 (22-51) and 47 (28-68) years, respectively, with bloody diarrhea the most common presenting symptom for each diagnosis. Lymphoma location was colorectal in nine (60%), small bowel in four (27%), and one (6.25%) each: stomach, duodenum, and ileal pouch. Treatments were surgery plus chemotherapy (n = 6), surgery alone (n = 3), chemotherapy alone (n = 2), chemotherapy and radiation (n = 1), surgery and radiation (n = 1); two patients died before treatment. Most patients (n = 11, 73%) were Ann Arbor stages I or II. Large cell B-type histology was most common (n = 9, 60%). Three patients died within 30 days of lymphoma diagnosis. Survival free of death from lymphoma at 1- and 5-years was 78% and 63%, respectively, and was associated with advanced lymphoma stage (P = 0.004). Conclusions: Diagnosis and treatment of primary intestinal lymphoma in patients with IBD can be challenging and requires a high index of suspicion. Optimal survival requires multimodality therapy.(Inflamm Bowel Dis 2010;)

KW - biologic therapy

KW - Crohn's disease

KW - gastrointestinal carcinogenesis

KW - inflammatory bowel disease

KW - infliximab

KW - surgery lymphoma

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=79958863060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958863060&partnerID=8YFLogxK

U2 - 10.1002/ibd.21516

DO - 10.1002/ibd.21516

M3 - Article

C2 - 21674712

AN - SCOPUS:79958863060

VL - 17

SP - 1557

EP - 1563

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 7

ER -